scholarly journals The Significance Of Hormone Receptors In Male Breast Cancer

2020 ◽  
Author(s):  
Yevhen Hotko
Keyword(s):  
Breast Cancer ◽  
Survival Rate ◽  
Hormone Therapy ◽  
Hormone Receptors ◽  
Malignant Tumors ◽  
Locally Advanced ◽  
Male Breast ◽  
Steroid Hormone Receptors ◽  
Malignant Neoplasms ◽  
Breast Cancer Patients

Abstract Background Male mammary glands are usually considered a rudimentary organ. However, they may be exposed to similar pathological influences as female breasts. These pathological influences may cause the development of malignant breast tumors. Breast cancer in males is a rare disease, nevertheless, it is a serious problem. According to numerous national cancer registries from around the world, this disease takes 1% on average in the structure of morbidity of malignant neoplasms of this organ in both sexes. Methods In our study (168 patients) estrogen receptors were positive in the tumors of 75% of patients. The positive rate of progesterone receptors was observed in 44% of patients. The detection rate of steroid hormone receptors in malignant tumors of the male breast ranges from 65 to 100%, depending on the criteria for identifying their positivity level. The hormone therapy in the early and late stages of cancer include antiestrogens, steroid and non-steroid aromatase inhibitors, both as monotherapy and in combination with LHRH-agonists, fulvestrant and other hormonal agents. Results There was no dependence found between the receptor status of the tumors and the age of patients with breast cancer. Breast cancer in men has a more aggressive course than the same disease in women. This means lower survival rate of male patients, greater number of locally advanced and metastatic cases, with delayed primary treatment, and resistance to treatment compared to female breast cancer patients. The incidence of receptor positive tumors in men does not increase with age, as observed in women with breast cancer. Despite numerous reports on the effectiveness of hormone therapy in men with breast cancer, many aspects of this type of therapy remain largely unexplained. Conclusions Hormone therapy appears the most effective in patients with the so-called feminization syndrome, which includes signs of hyperestrogenemia, as well as in patients with multiple unfavorable prognostic signs (stage III of cancer, low differentiation of tumor cells, status of regional lymph nodes N2-3, medium, severe and morbid obesity). Orchiectomy does not increase the survival rate, therefore, its application is impractical.

Prediction of response to neoadjuvant chemotherapy in breast cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 20005-20005
Author(s):  
J. Hannemann ◽  
H. Halfwerk ◽  
A. Velds ◽  
C. Loo ◽  
E. Rutgers ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Neoadjuvant Chemotherapy ◽  
Hormone Receptors ◽  
Locally Advanced Breast Cancer ◽  
Expression Patterns ◽  
Locally Advanced ◽  
Cdna Array ◽  
Steroid Hormone Receptors ◽  
Response To Neoadjuvant Chemotherapy

20005 Background: Neoadjuvant chemotherapy is increasingly employed in operable breast cancer. Our initial studies on a cDNA array platform failed to identify gene expression patterns predicting response to neoadjuvant chemotherapy in breast cancer patients (J Clin Oncol 23:3331, 2005). Now we included more patients and used oligo microarrays. Methods: Patients with operable or locally advanced breast cancer were included in a randomized phase II study or received neoadjuvant chemotherapy off protocol. All except 7 patients began chemotherapy with 3 courses of dose-dense adriamycin and cyclophosphamide (ddAC) and response was evaluated by MRI. Patients with a response and a HER2-positive tumor were then randomized between either 3 additional courses of ddAC or six weekly courses of carboplatin, paclitaxel and trastuzumab (CPT). Patients without response were switched to CPT. Patients with HER2-negative tumors were randomized between 3 courses of either ddAC or capecitabine and docetaxel (CD). After evaluation, patients without response were switched to the alternative treatment arm. From all patients 14G core needle biopsies were taken before treatment and total RNA was isolated. Amplified mRNA was labeled and hybridized to 35k human oligo microarrays from our microarray facility. Results: So far, 77 patients have been included into the study. From 48 of these, good quality RNA from tissue with >50% tumor cells was isolated. 43 patients had received ddAC as initial chemotherapy; 32 of these had not been switched to another regimen. In a training set containing 11 pathological complete remissions (pCR) and 9 non-responders (NR) we could separate these groups by using 20 genes in a supervised classification and a 9-step cross validation. These results could be validated in an independent set of 11 samples (6 pCR, 5 NR). From 10 out of 11 samples, response status could be predicted correctly, independent from the treatment regimen. Although ER-positive tumors have a lower pCR rate than ER-negative ones, the steroid hormone receptors were not present in the classifier. Conclusions: We conclude that it should be possible to identify a reliable gene expression profile associated with response to adriamycin based neoadjuvant chemotherapy in breast cancer. No significant financial relationships to disclose.

Measurement of steroid hormone receptors in breast cancer patients on tamoxifen

1993 ◽  
Vol 26 (3) ◽  
pp. 237-246 ◽  
Author(s):  
Carlos A. Encarnaci�n ◽  
Daniel R. Ciocca ◽  
William L. McGuire ◽  
Gary M. Clark ◽  
Suzanne A. W. Fuqua ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Hormone Receptors ◽  
Steroid Hormone ◽  
Steroid Hormone Receptors ◽  
Breast Cancer Patients

scholarly journals HORMONIOTERAPIA EM CÂNCER DE MAMA MASCULINO LOCALMENTE AVANÇADO: RELATO DE CASO / HORMONE THERAPY IN LOCALLY ADVANCED MALE BREAST CANCER: CASE REPORT

2020 ◽  
Vol 6 (12) ◽  
pp. 98902-98918
Author(s):  
Luiz Augusto Debona ◽  
Harry Francisco Monteiro de Lima ◽  
Taina Maria da Silva Perdigão ◽  
Flávio Lúcio Vasconcelos
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Hormone Therapy ◽  
Male Breast Cancer ◽  
Locally Advanced ◽  
Breast Cancer Case ◽  
Male Breast ◽  
Cáncer De Mama ◽  
Cancer Case

scholarly journals The Possible Impact of Obesity on Androgen, Progesterone and Estrogen Receptors (ERα and ERβ) Gene Expression in Breast Cancer Patients

2011 ◽  
Vol 5 ◽  
pp. BCBCR.S7707 ◽  
Author(s):  
R. Jahanban Esfahlan ◽  
N. Zarghami ◽  
A. Jahanban Esfahlan ◽  
M. Mollazadeh ◽  
K. Nejati ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Estrogen Receptors ◽  
Hormone Receptors ◽  
Steroid Receptors ◽  
Steroid Hormone ◽  
Mrna Level ◽  
Previous History ◽  
Steroid Hormone Receptors ◽  
Breast Cancer Patients

Background Obesity has been associated with increased mortality from hormone dependant cancers such as breast cancer which is the most prevalent cancer in women. The link between obesity and breast cancer can be attributed to excess estrogen produced through aromatization in adipose tissue. The role of steroid hormone receptors in breast cancer development is well studied but how obesity can affect the expression pattern of steroid hormones in patients with different grades of breast cancer was the aim of this study. Methods In this case-control study, 70 women with breast cancer participated with different grades of obesity (36 none obese, BMI < 25 kg/m2 and 34 obese, BMI ≥ 25 kg/m2). The mean age of participants was 44.53 ± 1.79 yr (21–70 yr). The serum level of estrogen, progesterone and androgen determined by ELISA. Following quantitative expression of steroid hormone receptors mRNA in tumor tissues evaluated by Real-time PCR. Patients with previous history of radiotherapy or chemotherapy were excluded. SPSS 16 was used for data analysis and P < 0.05 considered statistically significant. Results The difference in ERα, ERβ and PR mRNA level between normal and obese patients was significant ( P < 0.001). In addition, the expression of AR mRNA was found to be higher than other steroid receptors. There was no significant relation between ERβ gene expression in two groups ( P = 0.68). We observed a significant relationship between ERα and AR mRNA with tumor stage and tumor grade, respectively ( P = 0.023, P = 0.015). Conclusion According to the obtained results, it is speculated that obesity could paly a significant role in estrogen receptors gene expression and also could affect progression and proliferation of breast cancer cells.

scholarly journals A Study on Socio Demographic, Clinical Profile and Outcome of Breast Cancer Patients Attending Tertiary Cancer Care Centre in Gujarat State

Healthline ◽  
2021 ◽  
Vol 12 (1) ◽  
pp. 5-9
Author(s):  
Anand Shah ◽  
Ravi Patel ◽  
Jayesh Solanki ◽  
Vaishali Ravani
Keyword(s):  
Breast Cancer ◽  
Survival Rate ◽  
Cancer Patients ◽  
Clinical Presentation ◽  
Tertiary Care ◽  
Locally Advanced ◽  
Care Centre ◽  
Breast Cancer Patients ◽  
Tertiary Care Centre ◽  
Gujarat State

Introduction: Breast cancer is second most common cancer all over the world. Majority of breast cancer cases are registered to hospital at a later stage of cancer presentation. Objective: To study socio-demographic, clinical presentation and outcome of Breast cancer patients attending tertiary care centre of Gujarat state. Method: This was a retrospective study made up of 5774 patients registered in tertiary care centre of Gujarat state. Data including patient’s socio-demographic information like age, marital status, education level and clinical diagnosis including clinical presentation at time of registration, treatment history etc was collected. The data was analysed using MS office 2010 and Epi Info software version 7.0. Result: The age ranged between 17-99 years, with a median of 50 years and interquartile range of 42-58 years. There were 62.07% patients presented with locally advanced breast cancer, while 17.57% patients had distant metastasis at diagnosis. Significant association (p<0.05) was found between presentation of disease and literacy status. The overall Kaplan-Meier survival rate at 5 years was 35.8% + 5.0%. Survival rate was consistently declining with increase in clinical extension of disease. Conclusion: Majority of patients were in early advanced stage during their first hospital visit which was associated with poor survival. This information may help authorities to focus on early diagnosis of breast cancer.

scholarly journals Current Strategies of Endocrine Therapy in Elderly Patients with Breast Cancer

2018 ◽  
Vol 2018 ◽  
pp. 1-12 ◽  
Author(s):  
Suk-young Lee ◽  
Jae Hong Seo
Keyword(s):  
Breast Cancer ◽  
Elderly Patients ◽  
Hormone Therapy ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Hormone Receptors ◽  
Metastatic Breast ◽  
The Elderly ◽  
Breast Cancer Patients ◽  
Equivalent Efficacy

Currently, the growing population of the elderly is one of biggest problems in terms of increase in geriatric diseases. Lack of data from large prospective studies on geriatric breast cancer patients often makes it difficult for clinicians to make treatments decisions for them. Because both benefit and risk of treatment should be taken into account, treatment is usually determined considering life expectancy or comorbidities in elderly patients. Treatment of breast cancer is differentiated according to histologic classifications, and hormone therapy is even adopted for patients with metastatic breast cancer if tumor tissue expresses hormone receptors. Endocrine therapy can offer great benefit to elderly patients considering its equivalent efficacy to chemotherapy with fewer toxicities if it is appropriately used. Aromatase inhibitors are usually prescribed agents in hormone therapy for elderly breast cancer patients due to their physiology after menopause. Here, endocrine therapy for elderly patients with breast cancer in neoadjuvant, adjuvant, and palliative setting is reviewed along with predictive adverse events resulting from the use of hormone agents.

Steroid Hormone Receptors in Male Breast Cancer

1991 ◽  
Vol 14 (2) ◽  
pp. 123-125 ◽  
Author(s):  
Jules M. Elias ◽  
Allen Heimann ◽  
William Abel ◽  
Michelle Margiotta
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Hormone Receptors ◽  
Steroid Hormone ◽  
Male Breast ◽  
Steroid Hormone Receptors

scholarly journals Assessment of prognostic factors in breast cancer in women in Senegal: a review of 288 cases

2021 ◽  
Vol 1 (1) ◽  
pp. 6-9
Author(s):  
Mamadou Ndiaye ◽  
Souleymane Dieng ◽  
Jaafar Thiam ◽  
Adja Coumba Diallo ◽  
Doudou Diouf ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Prognostic Factors ◽  
Hormone Receptors ◽  
Ductal Carcinoma ◽  
Locally Advanced ◽  
Public Health Problem ◽  
Major Public Health Problem ◽  
Advanced Stage ◽  
Breast Cancer Patients

INTRODUCTION: In Senegal, breast cancer is the second female cancer and poses a major public health problem. The aim of this work was to assess prognostic factors in the progression of breast cancer in women. PATIENTS AND METHODS: This is a retrospective study carried out over a period of one year from January 1, 2008 to December 31, 2008 on all the women followed for breast cancer in the oncology department at the Joliot Curie Institute. Thus, 288 breast cancer patients were collected. RESULTS: The average age of our patients was 47.32 years. The average parity was 4.9 children per woman. Twenty-two or 7% of patients had a history of cancer. Clinically, the tumor size was classified as T4 in 180 patients, ie 81%. Lymph node involvement in 188 patients (65.2%). The most frequent histological type was invasive ductal carcinoma with 90.3% of cases. A predominance of grades SBRII and SBRIII was observed (respectively 41% and 46%). Hormone receptors (RH) were positive in eight cases (24%). Overexpression of the HER2 gene was found in only four out of 30 patients. The limits of the surgery were specified in 48 patients with invaded margins in seven patients (14.5%). The presence of vascular emboli was noted in 18 patients among the 29 whose research was carried out in 179 patients, ie 62%. At the time of the initial diagnosis, 45 patients or 19.7% of patients presented at least one distant metastasis. The majority of patients were received at an advanced stage (89%, classified between stage III and IV). Only one patient was received at stage I. Overall survival for breast cancer was 72% at 3 years and 30% at 5 years. The 5-year overall survival of patients with localized disease was 85% compared to 5% for patients with advanced stage. CONCLUSION: The prognostic factors are multiple and often pejorative in our patients with a predominance of young women, locally advanced cancers and aggressive biological forms.

Sign in / Sign up

Export Citation Format

Share Document